Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.1159/000515280
Abstract: Introduction: This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma. Methods: In this retrospective cohort study, 48 patients were treated with regorafenib for unresectable hepatocellular carcinoma. Thirty-five and… read more here.
Keywords: line; line regorafenib; 3rd line; 2nd 3rd ... See more keywords